Novo Nordisk A/S (ADR) news

   Watch this stock
Showing stories 1 - 10 of about 83   

Articles published

NVO 47.82 -0.58 (-1.20%)
price chart
Novo Nordisk And Eli Lilly Battling To Win GLP-1 Drug Market
Diabetes patients have a multitude of therapy options available, ranging from tablets and insulin therapies to the less common glucagon-like peptide-1 (GLP-1) agonists.
Related articles »  
Sanofi Still Ahead Of Novo Nordisk In Insulin Drug Race
The drug was run for non-inferiority tests against Novo's older insulin, Levemir. Moreover, both Levemir and Tresiba were combined to form mealtime insulin called Aspart or NovoRapid, which was commercialized in Europe.
Related articles »  
Novo, Orexigen Join Race For Obesity Drugs; Arena-Eisai's Belviq And Vivus's ...
Novo Nordisk A/S (ADR) (NVO) received the Food and Drug Administration's (FDA) approval on September 11 for its weight-loss therapy Saxenda, which was earlier prescribed as a treatment for diabetes.
Related articles »  
FDA Expected To Approve Two More Weight Loss Drugs
On the same day, the regulator has invited its advisors to come together and discuss Novo Nordisk A/S' (ADR) (NVO) intravenous injection to combat obesity.
Related articles »  
Higher gross margins are more profitable: Entergy Corporation (ETR), Novo ...
Novo Nordisk A/S (ADR) (NYSE:NVO) has 9.00% institutional ownership while its EPS ratio was 1.68. The company has 2.13 billion shares outstanding while market capitalization of the company was $101.97 billion.
Watch List - Novo Nordisk A/S (ADR) (NYSE:NVO), Cisco Systems, Inc ...
Manhattan, NY- 11 September, 2014 - (Techsonian) - Novo Nordisk A/S (ADR) (NYSE:NVO) engages in the discovery, development, manufacture, and marketing of pharmaceutical products primarily in Denmark.
Related articles »  
Watch List -Novo Nordisk A/S (ADR) (NYSE:NVO), FirstEnergy Corp. (NYSE:FE ...
Manhattan, NY- September 12, 2014 - (Techsonian) �Novo Nordisk A/S (ADR)( NYSE:NVO)engages in the discovery, development, manufacture, and marketing of pharmaceutical products primarily in Denmark.
Related articles »  
European stocks dip: Nokia Corporation (NYSE:NOK), Novo Nordisk A/S (NVO ...
Shares of Novo Nordisk A/S (ADR) (NYSE:NVO) were 46.41% off 52 week lows as of the latest close and -1.57% below the 52 week high.
Corporate Updates: KMG Chemicals, Inc. (NYSE:KMG), Novo Nordisk A/S (ADR ...
Novo Nordisk A/S (ADR) (NYSE:NVO) recently updated that the EMDAC (Endocrinologic and Metabolic Drugs Advisory Committee) of the U.S.
Blistering Penny Stocks in the News - Novo Nordisk A/S (NVO), AbbVieInc ...
Miami, Florida - 18 Sep, 2014 - (Tech Sonian)Novo Nordisk A/S (ADR) (NYSE:NVO)is announcing �Innovation in Diabetes Care: 90 Years and Beyond� at the MaRS Discovery District, to highlight the significant contribution Canada has made to diabetes care ...
Related articles »